Guides therapeutic decision-
18 days vs 31 days
with tissue testing.1,2*
Guardant360® is the comprehensive genomic profiling (CGP) liquid biopsy that identifies an expanded panel of actionable biomarkers.1,3
For patients with
advanced-stage cancer, especially those who have progressed on therapy.3
Detects an expanded
panel of biomarkers,
including TMB, MSI
status, HRR gene set, and
An expanded panel of biomarkers
Guardant360 covers 83 genes, including genes from the Guardant360® CDx panel, TMB, MSI status, and HRR.3
|Guardant360 Panel3,6||Guardant360 Panel3,6|
Liquid CGP testing provides guideline-complete genotyping more often than tissue-only testing.1
Resulted in guideline-complete genotyping in 95% of patients, compared with 18% in patients with tissue genotyping alone (n=268 for ctDNA arm; n=51 for tissue arm).1
Liquid CGP testing informs
treatment decisions sooner than tissue testing.2
Patients tested with Guardant360®
initiated targeted therapy
approximately 18 days following testing, compared with 31 days for those who underwent tissue biopsies. All patients responded to targeted
therapy similarly regardless of biopsy type.2
Treatment response results are comparable between liquid CGP testing and tissue testing.7
PFS rates in patients receiving
based on results from tissue vs ctDNA
NON-SMALL CELL LUNG
CANCER (NSCLC) DATA
- Guardant360® in combination with
tissue biopsy identified nearly 2X more patients with targeted biomarkers
versus tissue biopsy alone.8
NSCLC patients with targeted mutations detected by testing modality9
|Tissue + Guardant360||82|
- In rescue cases of QNS, 44% of tissue biopsy patients were unable to get results from tissue alone.9
across the cancer continuum.
Covered by MedicareContact client services ›
For all advanced solid tumors.
Easy access to test ordering and management with simple order forms.
Real-time updates on turnaround time.
Clear, concise reports, including therapy and clinical trial options.Sign in now ›
Easy and Convenient Sample Collection
A mobile phlebotomy service makesInquire about mobile phlebotomy ›
sample collection as easy and
convenient as possible by meeting
patients at their location.
Important Note: The Guardant360 test was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Palo Alto, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Guardant360 refers to Guardant360 Laboratory Developed Test (LDT). This test has not been cleared or approved by the US FDA.
*Non-small cell lung cancer patients who are negative from a plasma specimen for EGFR exon 19 deletions, L858R, T790M, EGFR exon 20 insertions, ERBB2/HER2 activating mutations and KRAS G12C should be reflexed to tissue biopsy testing using an FDA approved tumor tissue test, if feasible.10 Note that “tissue CGP,” known as Guardant360 TissueNext, and “liquid CGP test," known as Guardant360, have not been cleared or approved by the FDA. For the complete intended use statement including companion diagnostic indications, please see Guardant360 CDx Technical Information.
HRR, homologous recombinational repair; MSI, microsatellite instable; NTRK, neurotrophic tyrosine receptor kinase; QNS, quantity not sufficient; TMB, tumor mutation burden.
For a full list of diagnoses, download the Controlled Language for Diagnosis page.
For a full list of medical articles and drugs' Prescribing Information,
download the Gene Pocket Guide Reference List.